Masimo Corporation (MASI) is a leading player in medical technology with a razor-and-blade model that drives recurring revenues and customer stickiness. Despite a strong moat supported by proprietary IP and regulatory approvals, investor sentiment remains cautious due to previous diversification moves. However, with a refocused strategy, Masimo presents a compelling opportunity.

Masimo’s share price was $142.13 as of September 22nd, with a trailing P/E of 75.96 according to Yahoo Finance. The company’s Signal Extraction Technology (SET®) pulse oximetry platform is a standard of care in hospitals worldwide. Consumables make up over half of revenues, providing predictable margins and reinforcing customer loyalty. Despite risks such as pricing pressure and competition from Big Tech, Masimo’s durable protection comes from switching costs and strong IP.

Previously covered Medtronic plc (MDT) has seen a 17.27% increase in stock price since a bullish thesis in May 2025. Masimo’s consumables model and refocused healthcare franchise present a compelling opportunity amidst investor skepticism. The company’s strong fundamentals, recurring revenues, and strategic realignment make it an intriguing investment choice.

Read more at Yahoo Finance: Masimo Corporation (MASI): A Bull Case Theory